In the phase Ib study assessing the activity of T-DXd in patients with HER2-low metastatic BC, patients mostly had HR-positive disease (87%), harbored visceral disease at baseline and were heavily pretreated (median 7.5 prior therapies) [63]. The gene discussed is ERBB2; the disease is breast cancer.